Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says Alkindi, its hydrocortisone granules in capsules for opening, product sales for the six months ended December 31 increased to GBP1.2 million, up 4% year-on-year from GBP1.1 million. Says total revenue, including licence income, up 6% year on year to GBP1.2 million.
Chief Executive Martin Whitaker says: "Diurnal is pleased that Alkindi revenues have continued to grow despite the significant challenges in access to hospitals due to Covid-19 pandemic restrictions, impacting both patients and our commercial team.
"The trajectory of Alkindi growth in the second half of the financial year, and hence our full year product sales, will be dependent on when the pandemic restrictions are eased; however, we expect as a minimum to maintain reasonable growth in our core commercial markets and believe, once the pandemic has eased, growth will significantly accelerate. We are also pleased with the continued geographic expansion for Alkindi, highlighting the value for patients across the globe, and look forward to announcing further partnerships in due course."
Current stock price: 61.00 pence
Year-to-date change: up 7.0%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
